| Cat.No. | Name | Information |
|---|---|---|
| M2304 | TWS119 | TWS119 is a GSK-3β inhibitor with IC50 of 30 nM. |
| M1989 | CHIR-99021 HCl | CHIR-99021 HCl (Laduviglusib; CT99021) is a hydrochloride of CHIR-99021, with IC50 of 10 nM and 6.7 nM for GSK-3α and GSK-3β, respectively. |
| M1692 | CHIR-99021 | CHIR-99021 (CT99021) is an aminopyrimidine derivative that inhibits GSK3α and GSK3β with IC50 values of 10 and 6.7 nM, respectively. |
| M49757 | GSK-3β inhibitor 2 | GSK-3β inhibitor 2 is a potent, selective and orally active GSK-3β inhibitor with an IC50 of 1.1 nM. |
| M29929 | GSK3-IN-3 | GSK3-IN-3 is a mitophagy inducer, inducing Parkin-dependent mitophagy. GSK3-IN-3 is also a GSK-3 inhibitor with an IC50 value of 3.01 μM. GSK3-IN-3 is non-ATP nor substrate competitive and is neuroprotective against 6-OHDA. |
| M21232 | MeBIO | MeBIO, an analog of 6-bromoindirubin-3'-oxime, has been suggested to possess the structural basis for a potent and selective inhibitor of glycogen synthase kinase-3 (GSK3) and cyclin-dependent kinases. MeBIO displays minimal activity against CDK1/Cyclin B, GSK-3, and CDK5/p25 (IC50 values are 92.0, 44-100 and >100 μM respectively). MeBIO is a potent AhR (aryl hydrocarbon receptor) agonist. |
| M20731 | Elraglusib | Elraglusib (9-ING-41) is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with antitumor activity. Elraglusib induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK3β. |
| M14839 | KY19382 | KY19382 is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β, with IC50s of 19 and 10 nM, respectively. |
| M10548 | TSPC | TSPC (HUN86320) is a Glycogen Synthase Kinase-3β Inhibitor (GSK-3β Inhibitor). |
| M10531 | BRD3731 | BRD3731 is a selective GSK3β inhibitor, with IC50s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. |
| M10530 | BRD0705 | BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor with an IC50 of 66 nM and a Kd of 4.8 μM. |
| M10108 | Indirubin-3'-monoxime | Indirubin-3'-monoxime is a potent GSK-3β inhibitor with IC50 of 22 nM, and inhibits Cdk5/p35, Cdk1/cyclin-B and Cdk2/cyclin-E with IC50s of 100, 180, 250 nM. |
| M8385 | BIO-Acetoxime | BIO-Acetoxime is a potent and selective GSK-3a/b inhibitor that reduces invasiveness of gliomas and extends animal survival in intracranial glioma models. |
| M8272 | BIP-135 | BIP-135 is a potent inhibitor of glycogen synthase kinase-3 (GSK3) found to be relatively selective for GSK-3β (21 nM) over GSK-3α with modest activity toward PKCβ (β1: 980 nM; β2: 219 nM), DYRK1B (590 nM), and PI3Kα (870 nM). |
| M8228 | Bikinin | Bikinin is a strong activator of brassinosteroid (BR) signaling. |
| M7742 | DIF-3 | DIF-3 inhibits cell cycle by inducing G0/G1 arrest. DIF-3 reduces the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β. DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in DLD-1 cells. |
| M7627 | BIO | BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052) is a specific GSK-3 inhibitor, the IC50 acting on GSK-3α/β in cell-free assays is 5 nM, which is more than 16 times more selective than ACTing on CDK5. It is also a pan-JAK inhibitor with an IC50 value of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells. |
| M6594 | CHIR 99021 trihydrochloride | Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib trihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib trihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. |
| M6360 | A 1070722 | A 1070722 is a highly potent, selective GSK-3 inhibitor. |
| M6337 | 3F8 | 3F8 is a potent and selective GSK-3β inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
